Actemra 80 mg/4ml 1 vial

Actemra (active ingredient tocilizumab) in the 80 mg/4 mL strength is a biologic medication typically used as a concentrated solution for intravenous (IV) infusion.

Product Specifications
Formulation: Each single-dose vial contains 80 mg of tocilizumab in 4 mL of sterile solution, providing a concentration of 20 mg/mL.
Administration: This specific vial is intended for IV infusion and must be diluted by a healthcare professional before being administered over a 60-minute period.
Manufacturers: Primarily manufactured by Roche (or its subsidiary Genentech).

Common Uses
Actemra is an interleukin-6 (IL-6) receptor antagonist used to treat various inflammatory and autoimmune conditions:

Rheumatoid Arthritis (RA): For adults with moderate to severe active RA.
Juvenile Idiopathic Arthritis: Used for both polyarticular (PJIA) and systemic (SJIA) forms in children.
Cytokine Release Syndrome (CRS): Treatment for severe or life-threatening CRS induced by CAR T-cell therapy.
COVID-19: Indicated for hospitalised adults receiving corticosteroids who require supplemental oxygen or mechanical ventilation.

Safety & Side Effects

Boxed Warning: Actemra carries a warning for serious infections (e.g., tuberculosis, bacterial, or fungal infections) that may lead to hospitalisation.
Common Side Effects: Upper respiratory tract infections, headache, high blood pressure, and injection site reactions.
Interactions: May interact with other biologics (e.g., adalimumab, etanercept) or certain cholesterol medications.